
News|Articles|November 1, 2005
Pipeline Preview
Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Non-approvable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?
2
FDA approves first postmenopausal libido treatment, Addyi
3
Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk
4
Pharmacy leaders in ASHP survey worry about 340B program changes
5






















































